The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Epigenetics of Alzheimer’s Disease
Open accessAbstract
There are currently no validated biomarkers which can be used to accurately diagnose Alzheimer’s disease (AD) or to distinguish it from other dementia-causing neuropathologies. Moreover, to date, only symptomatic treatments exist for this progressive neurodegenerative disorder. In the search for new, more reliable biomarkers and potential therapeutic options, epigenetic modifications have emerged as important players in the pathogenesis of AD. The aim of the article was to provide a brief overview of the current knowledge regarding the role of epigenetics (including mitoepigenetics) in AD, and the possibility of applying these advances for future AD therapy. Extensive research has suggested an important role of DNA methylation and hydroxymethylation, histone posttranslational modifications, and non-coding RNA regulation (with the emphasis on microRNAs) in the course and development of AD. Recent studies also indicated mitochondrial DNA (mtDNA) as an interesting biomarker of AD, since dysfunctions in the mitochondria and lower mtDNA copy number have been associated with AD pathophysiology. The current evidence suggests that epigenetic changes can be successfully detected, not only in the central nervous system, but also in the cerebrospinal fluid and on the periphery, contributing further to their potential as both biomarkers and therapeutic targets in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53221.x · Cited by 25,553 · cited 1×
“The diagnosis is based on the confirmation of memory loss and cognitive difficulties using neurological tests such as the Montreal Cognitive Assessment (MoCA) [17] and Mini-Mental Status Examination (MMSE) [18].”
MethodMcKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
The widespread regulation of microRNA biogenesis, function and decay
Krol, J., Loedige, I., & Filipowicz, W. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2843 · Cited by 4,672
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345 · cited 1×
“The etiology of AD is still not clear, however, neuroinflammation, extracellular plaques, and intracellular neurofibrillary tangles are the key pathological markers of the disease [10].”
BackgroundAgeing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310 · cited 1×
“Since aging is the main risk factor for neurodegenerative diseases, the prevalence of AD increases with human longevity [5].”
BackgroundThe Nuclear DNA Base 5-Hydroxymethylcytosine Is Present in Purkinje Neurons and the Brain
Kriaucionis, S., & Heintz, N. (2009) · Science · doi:10.1126/science.1169786 · Cited by 2,700 · cited 1×
“DNA hydroxymethylation was first described in 1972 [30], but it was not until 2009 that it was identified as an oxidation metabolite of DNA methylation [31,32].”
BackgroundGene silencing by microRNAs: contributions of translational repression and mRNA decay
Huntzinger, E., & Izaurralde, E. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2936 · Cited by 2,339
Histone methylation: a dynamic mark in health, disease and inheritance
Greer, E. L., & Shi, Y. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3173 · Cited by 2,241
Editing DNA Methylation in the Mammalian Genome
Liu, X. S., Wu, H., Ji, X., Stelzer, Y., Wu, X., Czauderna, S., Shu, J., Dadon, D., Young, R. A., & Jaenisch, R. (2016) · Cell · doi:10.1016/j.cell.2016.08.056 · Cited by 1,224
Alzheimer's disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci
De Jager, P. L., Srivastava, G., Lunnon, K., Burgess, J., Schalkwyk, L. C., Yu, L., Eaton, M. L., Keenan, B. T., Ernst, J., McCabe, C., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3786 · Cited by 956
Cogswell, J. P., Ward, J., Taylor, I. A., Waters, M., Shi, Y., Cannon, B., Kelnar, K., Kemppainen, J., Brown, D., Chen, C., et al. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14103 · Cited by 943 · cited 8×
“Braak III-VI (n = 20), Braak 0-I (n = 7) CNS (HPC, MFG, CB)/RT-qPCR [152] AD (n = 3/10), MCI (n = 10), Ctrl (n = 3/12) CNS (FCx)/array and RT-qPCR [196]”
InfluentialThe genetic landscape of Alzheimer disease: clinical implications and perspectives
Van Cauwenberghe, C., Van Broeckhoven, C., & Sleegers, K. (2016) · Genetics in Medicine · doi:10.1038/gim.2015.117 · Cited by 863 · cited 4×
“This form of AD is associated with mutations in genes coding for APP, presenilin-1 (PSEN1), and PSEN2 [13].”
BackgroundInfluentialBeyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogation
Dominguez, A. A., Lim, W. A., & Qi, L. S. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2015.2 · Cited by 832 · cited 1×
“The mutant form of the Cas9, called dead Cas9 (dCas9), advanced the CRISPR/Cas9 gene editing tool and resulted in CRISPR interference (CRISPRi) technology, when dCas9 is fused or interacts with transcriptional repressors, and in CRISPR activation (CRISPRa) technology, when dCas9 is fused or interacts with transcriptio…”
BackgroundThe Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.010 · Cited by 786
Multiple roles of HDAC inhibition in neurodegenerative conditions
Chuang, D.-M., Leng, Y., Marinova, Z., Kim, H.-J., & Chiu, C.-T. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.06.002 · Cited by 676
Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease
Lunnon, K., Smith, R., Hannon, E., De Jager, P. L., Srivastava, G., Volta, M., Troakes, C., Al-Sarraj, S., Burrage, J., Macdonald, R., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3782 · Cited by 574
Coskun, P. E., Beal, M. F., & Wallace, D. C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403649101 · Cited by 556 · cited 1×
“In mtDNA, several extensive deletions have been reported to be associated with AD [83], as well as mutations of cytochrome c oxidase [84], tRNAs and rRNAs [85,86], and mutations in the regulatory D-loop, which affect transcription, translation, and mtDNA copy number [87].”
BackgroundAltered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease
Gui, Y., Liu, H., Zhang, L., Lv, W., & Hu, X. (2015) · Oncotarget · doi:10.18632/oncotarget.6158 · Cited by 552
Methyl-cpG-binding domain proteins: readers of the epigenome
Du, Q., Luu, P.-L., Stirzaker, C., & Clark, S. J. (2015) · Epigenomics · doi:10.2217/epi.15.39 · Cited by 544
Tau promotes neurodegeneration through global chromatin relaxation
Frost, B., Hemberg, M., Lewis, J., & Feany, M. B. (2014) · Nature Neuroscience · doi:10.1038/nn.3639 · Cited by 495 · cited 2×
“Oxidative stress and subsequent DNA damage have been identified as a mechanistic link between transgenic tau expression and heterochromatin relaxation [117].”
BackgroundSeo, S.-B., McNamara, P., Heo, S., Turner, A., Lane, W. S., & Chakravarti, D. (2001) · Cell · doi:10.1016/s0092-8674(01)00196-9 · Cited by 481
Lukiw, W. J., Zhao, Y., & Cui, J. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805371200 · Cited by 441
Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States
Brookmeyer, R., Abdalla, N., Kawas, C. H., & Corrada, M. M. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.10.009 · Cited by 406 · cited 2×
“08 million people in the United States [8], while AD prevalence in Europe was estimated at 5.”
BackgroundInfluentialBurgos, K., Malenica, I., Metpally, R., Courtright, A., Rakela, B., Beach, T., Shill, H., Adler, C., Sabbagh, M., Villa, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094839 · Cited by 385
miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model
Lee, S., Chu, K., Jung, K., Kim, J. H., Huh, J., Yoon, H., Park, D., Lim, J., Kim, J., Jeon, D., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23588 · Cited by 326
Marked changes in mitochondrial DNA deletion levels in Alzheimer brains
Corral-Debrinski, M., Horton, T., Lott, M. T., Shoffner, J. M., McKee, A. C., Beal, M. F., Graham, B. H., & Wallace, D. C. (1994) · Genomics · doi:10.1006/geno.1994.1525 · Cited by 309 · cited 1×
“In mtDNA, several extensive deletions have been reported to be associated with AD [83], as well as mutations of cytochrome c oxidase [84], tRNAs and rRNAs [85,86], and mutations in the regulatory D-loop, which affect transcription, translation, and mtDNA copy number [87].”
BackgroundCui, J. G., Li, Y. Y., Zhao, Y., Bhattacharjee, S., & Lukiw, W. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.178848 · Cited by 274
Wang, X., Liu, P., Zhu, H., Xu, Y., Ma, C., Dai, X., Huang, L., Liu, Y., Zhang, L., & Qin, C. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.08.006 · Cited by 271
Autosomal Recessive Causes Likely in Early-Onset Alzheimer Disease
Wingo, T. S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.221 · Cited by 265
Epigenetic regulation in the pathophysiology of Alzheimer's disease
Chouliaras, L., Rutten, B. P. F., Kenis, G., Peerbooms, O., Visser, P. J., Verhey, F., van Os, J., Steinbusch, H. W. M., & van den Hove, D. L. A. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.01.002 · Cited by 262
Bakulski, K. M., Dolinoy, D. C., Sartor, M. A., Paulson, H. L., Konen, J. R., Lieberman, A. P., Albin, R. L., Hu, H., & Rozek, L. S. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-111223 · Cited by 255
Geekiyanage, H., & Chan, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3883-11.2011 · Cited by 254
Locus-specific histone deacetylation using a synthetic CRISPR-Cas9-based HDAC
Kwon, D. Y., Zhao, Y.-T., Lamonica, J. M., & Zhou, Z. (2017) · Nature Communications · doi:10.1038/ncomms15315 · Cited by 246
Evidence for miR‐181 involvement in neuroinflammatory responses of astrocytes
Hutchison, E. R., Kawamoto, E. M., Taub, D. D., Lal, A., Abdelmohsen, K., Zhang, Y., Wood, W. H., Lehrmann, E., Camandola, S., Becker, K. G., et al. (2013) · Glia · doi:10.1002/glia.22483 · Cited by 246
MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer`s Disease
Denk, J., Boelmans, K., Siegismund, C., Lassner, D., Arlt, S., & Jahn, H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126423 · Cited by 236
Li, P., Marshall, L., Oh, G., Jakubowski, J. L., Groot, D., He, Y., Wang, T., Petronis, A., & Labrie, V. (2019) · Nature Communications · doi:10.1038/s41467-019-10101-7 · Cited by 234 · cited 1×
“A DNA methylation decrease was observed in the prefrontal cortex and locus coeruleus [49,54].”
Marzi, S. J., Leung, S. K., Ribarska, T., Hannon, E., Smith, A. R., Pishva, E., Poschmann, J., Moore, K., Troakes, C., Al-Sarraj, S., et al. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0253-7 · Cited by 232 · cited 4×
“, GABA receptor activity, synaptic proteins) [118].”
BackgroundInfluentialCirculating miRNAs as Potential Biomarkers in Alzheimer's Disease
Galimberti, D., Villa, C., Fenoglio, C., Serpente, M., Ghezzi, L., Cioffi, S. M. G., Arighi, A., Fumagalli, G., & Scarpini, E. (2014) · Journal of Alzheimer’s Disease · doi:10.3233/jad-140756 · Cited by 222
MiR-107 is Reduced in Alzheimer's Disease Brain Neocortex: Validation Study
Nelson, P. T., & Wang, W.-X. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091603 · Cited by 222
Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer’s disease
Tanimukai, H., Grundke-Iqbal, I., & Iqbal, K. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62486-8 · Cited by 220
Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease
Podlesniy, P., Figueiro‐Silva, J., Llado, A., Antonell, A., Sanchez‐Valle, R., Alcolea, D., Lleo, A., Molinuevo, J. L., Serra, N., & Trullas, R. (2013) · Annals of Neurology · doi:10.1002/ana.23955 · Cited by 219
Targeted DNA methylation in vivo using an engineered dCas9-MQ1 fusion protein
Lei, Y., Zhang, X., Su, J., Jeong, M., Gundry, M. C., Huang, Y.-H., Zhou, Y., Li, W., & Goodell, M. A. (2017) · Nature Communications · doi:10.1038/ncomms16026 · Cited by 218
Neuronal MicroRNA Deregulation in Response to Alzheimer's Disease Amyloid-β
Schonrock, N., Ke, Y. D., Humphreys, D., Staufenbiel, M., Ittner, L. M., Preiss, T., & Götz, J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011070 · Cited by 211
Watson, C. T., Roussos, P., Garg, P., Ho, D. J., Azam, N., Katsel, P. L., Haroutunian, V., & Sharp, A. J. (2016) · Genome Medicine · doi:10.1186/s13073-015-0258-8 · Cited by 201
Blanch, M., Mosquera, J. L., Ansoleaga, B., Ferrer, I., & Barrachina, M. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.10.004 · Cited by 192 · cited 2×
“found increased mtDNA methylation at CpG and non-CpG sites of D-loop in the entorhinal cortex of AD patients with Braak stages I to II and III to IV, when compared to control subjects [102].”
BackgroundLong, J. M., Ray, B., & Lahiri, D. K. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.518241 · Cited by 187
Smith, R. G., Hannon, E., De Jager, P. L., Chibnik, L., Lott, S. J., Condliffe, D., Smith, A. R., Haroutunian, V., Troakes, C., Al‐Sarraj, S., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.017 · Cited by 184
Evidence of DNA damage in Alzheimer disease: phosphorylation of histone H2AX in astrocytes
Myung, N.-H., Zhu, X., Kruman, I. I., Castellani, R. J., Petersen, R. B., Siedlak, S. L., Perry, G., Smith, M. A., & Lee, H.-G. (2008) · AGE · doi:10.1007/s11357-008-9050-7 · Cited by 170
Epigenetic regulation: A new frontier for biomedical engineers
Chen, Z., Li, S., Subramaniam, S., Shyy, J. Y.-J., & Chien, S. (2017) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071516-044720 · Cited by 163
Hampel, H., O’Bryant, S. E., Durrleman, S., Younesi, E., Rojkova, K., Escott-Price, V., Corvol, J.-C., Broich, K., Dubois, B., Lista, S., et al. (2017) · Climacteric · doi:10.1080/13697137.2017.1287866 · Cited by 147 · cited 1×
“disorder, which represents the most common cause of dementia in older populations, and a major health problem worldwide [3].”
BackgroundRohn, T. T., Vyas, V., Hernandez-Estrada, T., Nichol, K. E., Christie, L.-A., & Head, E. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5620-07.2008 · Cited by 146
Hébert, S. S., Wang, W.-X., Zhu, Q., & Nelson, P. T. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122350 · Cited by 125
Sabbagh, M. N., Lue, L.-F., Fayard, D., & Shi, J. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0069-5 · Cited by 107 · cited 1×
“The biggest problem in AD is accurate diagnosis, estimated to be around 77%, as it relies on the clinical criteria and presence of the symptoms [22].”
BackgroundPogue, A. I., & Lukiw, W. J. (2018) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-017-0572-3 · Cited by 105
Tian, N., Cao, Z., & Zhang, Y. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1419-7 · Cited by 93
Fernandes, A., Ribeiro, A. R., Monteiro, M., Garcia, G., Vaz, A. R., & Brites, D. (2018) · Biochimie · doi:10.1016/j.biochi.2018.05.015 · Cited by 93
Spreading of Alzheimer’s disease inflammatory signaling through soluble micro-RNA
Lukiw, W. J., Alexandrov, P. N., Zhao, Y., Hill, J. M., & Bhattacharjee, S. (2012) · NeuroReport · doi:10.1097/wnr.0b013e32835542b0 · Cited by 90
Tsujio, I., Zaidi, T., Xu, J., Kotula, L., Grundke-Iqbal, I., & Iqbal, K. (2005) · FEBS Letters · doi:10.1016/j.febslet.2004.11.097 · Cited by 80
DNA Hypomethylation in Blood Links B3GALT4 and ZADH2 to Alzheimer’s Disease
Madrid, A., Hogan, K. J., Papale, L. A., Clark, L. R., Asthana, S., Johnson, S. C., & Alisch, R. S. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180592 · Cited by 77
Zhou, Y., Deng, J., Chu, X., Zhao, Y., & Guo, Y. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-181053 · Cited by 71
CHANG, F., ZHANG, L.-H., XU, W.-P., JING, P., & ZHAN, P.-Y. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2013 · Cited by 59
Cited by
Oxidative Stress and Beta Amyloid in Alzheimer’s Disease. Which Comes First: The Chicken or the Egg?
Tamagno, E., Guglielmotto, M., Vasciaveo, V., & Tabaton, M. (2021) · Antioxidants · doi:10.3390/antiox10091479 · Cited by 264
Pathophysiology of Alzheimer’s Disease
Yarns, B. C., Holiday, K. A., Carlson, D. M., Cosgrove, C. K., & Melrose, R. J. (2022) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2022.07.003 · Cited by 68
Wang, K., Yang, R., Li, J., Wang, H., Wan, L., & He, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1591438 · Cited by 27
Modulation of microRNAs through Lifestyle Changes in Alzheimer’s Disease
Pinto-Hernandez, P., Castilla-Silgado, J., Coto-Vilcapoma, A., Fernández-Sanjurjo, M., Fernández-García, B., Tomás-Zapico, C., & Iglesias-Gutiérrez, E. (2023) · Nutrients · doi:10.3390/nu15173688 · Cited by 22
Metadata
- Authors
- Nikolac Perkovic, M., Videtic Paska, A., Konjevod, M., Kouter, K., Svob Strac, D., Nedic Erjavec, G., & Pivac, N.
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2021-01-30
- Volume
- 11
- Issue
- 2
- Pages
- 195
- ISSN
- 2218-273X (ISSN-L)
- OpenAlex
- W3126654127
- Cited by
- 176
- References
- 64
- FWCI
- 15.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.